Figure 3.
Ibrutinib plus venetoclax normalizes abnormal T-cell counts to healthy donor levels within the first 6 months of treatment. (A) Absolute counts of regulatory T cells. (B) Absolute counts of LTA T cells. (C) Absolute counts of PD-1+ T cells. (D) Absolute counts of γδ T cells. Data points represent median values, and error bars represent the IQR.

Ibrutinib plus venetoclax normalizes abnormal T-cell counts to healthy donor levels within the first 6 months of treatment. (A) Absolute counts of regulatory T cells. (B) Absolute counts of LTA T cells. (C) Absolute counts of PD-1+ T cells. (D) Absolute counts of γδ T cells. Data points represent median values, and error bars represent the IQR.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal